September 19-20 2024

Dear All, 

It is our pleasure to announce the WG1 WG2 HG7 Thematic Workshop:   " Novel leads and drugs for vector borne diseases: Targets and off targets (toxicity and ecotoxicity) and mechansim of action” that will take place next September 19-20 2024 at the National Hellenic Research Foundation, Athens, Greece.

The official anouncement will soon be published, as the workshop is open to all scientists.

As usual, we will do our best to support as many attendants as possible. For that we need to proceed in two directions. In one side we have to finish the reimboursements for june and july events (Naples training school, Rome YRI workshop and Ofxord Conference). If you attended any of them as "eligible for reimboursement", please proceed claiming your expenses ASAP.  

In the other side we would like to know who is planning to attend the Athens Workshop and how much that will cost. 

PREREGISTRATION before August 5th can be performedhttps://docs.google.com/forms/d/e/1FAIpQLSflZJMFa4m6QXa5B9ZxXCZp8doOurXLk2pJh71SK9rPziJaHw/viewform?usp=sharing

In case you need a letter for VISA application, please write the letter yourself and send it to the Chair (Maria Paola COSTI ) who will follow up on that with you.

-----------------

Description

We are excited to announce the international workshop “Novel leads and drugs for vector borne diseases: Targets and off targets (toxicity and ecotoxicity) and mechanism of action” organized in the context of the COST ACTION 2111-OneHealthdrugs – “One Health drugs against parasitic vector borne diseases in Europe and beyond”. The COST Action network aims to coordinate the discovery of drugs that stop vector-borne infections in both human and veterinary settings according to the principles of the optimal profile for these organisms, increasing quality and reducing environmental impact. 

The workshop will be held from Thursday, September 19th, to Friday, September 20th ,2024, in Athens, Greece, at the National Hellenic Research Foundation. The workshop is jointly organized by WG1 “Compound libraries coordination and integration of compound design”, WG2 “Integration of early phase studies and low environmental impact actions”, and HG7 “Drug chemistry advancements in biodegradability including prediction” of the COST Action CA21111 OneHealthDrugs.

The workshop seeks to provide up to date information and integration strategy on sustainable drug discovery for vector borne diseases (VBDs). Special emphasis will also be given to new targets for VBDs and methods to study their engagement as well as on biodegradability and toxicity aspects pinpointing the effect on the environment. This collaborative event will provide a platform for scientists, academics, and industry professionals to share insights, methodologies, and advancements in the pursuit of environmentally conscious antiparasitic drug discovery. 

We look forward to your participation and the submission of your abstract and we are delighted to welcome you in Athens to this intellectually rewarding meeting.

With warm regards, 

The Scientific Committee

Theodora Calogeropoulou, National Hellenic Research Foundation, Athens, Greece

Ulrike Wittig, Heidelberg Institute for Theoretical Studies, Heidelberg, Germany

Sandra Gemma, University of Siena, Siena, Italy

Maria Paola Costi, University of Modena and Reggio Emilia

Anabela Cordeiro da Silva

The Local Organising Committee

Theodora Calogeropoulou

Ioannis Papanastastiou

George E. Magoulas

Theano Fotopoulou

 

 

 

Abstract template

Final Programme_Novel leads and drugs for vector borne diseases: Targets and off targets (toxicity and ecotoxicity) and mechanism of action

Book of Abstracts Novel leads and drugs for vector borne diseases: Targets and off targets (toxicity and ecotoxicity) and mechanism of action”

Index of Abstracts

 

Oral communication

  1. Innovative approaches to target trypanothione reductase an essential enzyme for the survival of trypanosomatids in the host…………………………………………………………………………………...xx
  2. Cyclic AMP signaling and nucleoside activated Protein Kinase A in Trypanosoma and Leishmania: genetic target validation and structure-guided inhibitor design………………………………………………………xx
  3. Chemical tools to decipher the modes of action of antiplasmodial redox-active 3-benzylmenadiones……….xx
  4. Unravelling the mechanism of action of highly potent Pteridine Reductase 1 inhibitors: new insights into dual targeting of PTR1 and DHFR…………………………………………………………………………………xx
  5. Phenotypic and target-based screening of nucleoside analogues as antitrypanosomal agents………………..xx
  6. Specialized pro-resolving mediators as leads for resolution pharmacology targeting vector borne diseases…xx
  7. Robenidine Derivatives As Potential Antischistosomal Drug Candidates……………………………………xx
  8. Synthesis and Anti-Parasitic Evaluation of Fused N,S-Heterocyclic Derivatives……………………………xx
  9. Discovery and preliminary preclinical in vivo evaluation of a dicationic candidate for the oral treatment of leishmaniasis………………………………………………………………………………………………….xx
  10. Arnica tincture is effective against cutaneous Leishmaniasis in human patients: A novel drug for this vector borne disease without toxic or ecotoxicological impact………………………………………………………xx
  11. Drug Discovery and Development for Human and Animal African Trypanosomiasis: A Comprehensive Database of Natural Compounds with Anti-trypanosomal Activity………………………………………….xx
  12. G.AI.A. A computational platform for ecotoxicity predictions of chemical compounds…………………….xx
  13. Optimizing Trypanothione Reductase Inhibitors for Leishmania Treatment: A Multiparametric Prediction Approach to Enhance Solubility and Biodegradability……………………………………………………….xx
  14. Development of NMT-A004-loaded biodegradable nanocarriers…………………………………………….xx
  15. One Health Approach in Drug Discovery for Leishmaniasis by Targeting Calpain cys-protease…………….xx
  16. Innovative Therapeutic Strategies for Vector-Borne Diseases: Exploring Novel Drug Targets and Addressing Off-Target Toxicity…………………………………………………………………………………………...xx
  17. Bioethical and human security approaches on evolution of drugs for vector borne diseases…………………xx
     
  18.  
  19. Antitrypanosomal activity of D-ring modified steroid derivatives…………………………………………….xx
  20. Toxicity, repellency, and anti-cholinesterase activities of essential oil and crude extracts of Ruta chalepensis, against vector of several major pathogenic diseases in livestock and poultry in Tunisia……………………..xx
  21. Activity of novel heterocyclic compounds against promastigote and amastigote-like Leishmania infantum and Leishmania tropica……………………………………………………………………………………………xx
  22. Molecular modelling on antiparasitic nucleoside drugs: revealing mechanism of drug action……………….xx
  23. Pathogens and vectors of zoonosis and vector borne diseases in Albania; a literature review……………….xx
  24. Analyzing High Throughput Malaria Rapid Diagnostic Test Effectiveness and Genetic Diversity in Dominican Republic: Considerations for Elimination Efforts…………………………………………………………….xx
  25. Synthesis and biological evaluation of new antiparasitic 4-thiazolidinone bioisosters of alkylphosphocholines…………………………………………………………………………………………xx
  26. Plasmodium falciparum type-II NADH:ubiquinone:oxidoreductase as a possible target for bioreductively activated antiplasmodial agents……………………………………………………………………………….xx
  27. Detection of Strongyloides stercoralis during the control of school-aged children in a rural area of Tirana…xx
  28. Vivax malaria cases imported from Greece during 2010-2016……………………………………………….xx
  29. Novel Napthyl Indolyl maleimides (NIM’s) as inhibitors of kinase and new leads in the treatment of Leishmaniasis…………………………………………………………………………………………………xx
  30. Comparative analysis of activated cysteine residues in human and parasitic enzymes: potential for covalent inhibition……………………………………………………………………………………………………...xx
  31. Molecular Detection of Filarial Nematode Parasites In Mosquitoes From Albania………………………….xx
  32. Adamantane Nitro-Heterocyclic Derivatives with Activity against L. infantum……………………………..xx

 

COST
What is COST?

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. The COST ACTIONS help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

OneHealthdrugs CA21111
Title:

One Health drugs against parasitic vector borne diseases in Europe and beyond

Acronym:

OneHealthdrugs

Start date of the Action:

24/10/2022

End date of the Action:

23/10/2026

CSO approval date:

27/05/2022

Memorandum of Understanding (MoU)

Download file

Contact Points
Chair:

Maria Paola Costi

Vice-Chair:

Anabela Cordeiro da Silva

COST staff

Scientific Officer:
Lucia Forzi
Administrative Officer:
Nathalie Warenghien

Administrative Team

Maria Cristina Notarsanto
Maria Esposito and Laura Leonardi